AUTHORS
Gao Yan, PhD, Xue-Ping Li2, Xuan-Ye Zhang3, Jicheng Hong4, Xiaolei Wei5, Qichun Cai, PhD6, Li-Qin Ping7, Huiqiang Huang, MD, PhD8
AFFILIATIONS
1 Sun Yat-sen University Cancer Center, Guangzhou, China
2 Sun Yat-sen University Cancer Center, Guangzhou, China
3 Sun Yat-sen University Cancer Center, Guangzhou, China
4 Sun Yat-sen University Cancer Center, Guangzhou, China
5 Nanfang Hospital, Southern Medical University, Guangzhou, China
6 Cancer Center, Clifford Hospital, Guangzhou, China
7 The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China
8 Sun Yat-sen University Cancer Center, Guangzhou, China
ABSTRACT
Background:
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Standard R-CHOP cures ~60% of patients, but 30%–40% relapse and ~10% are primary refractory. For relapsed/refractory (R/R) DLBCL, salvage chemotherapy has limited efficacy; the SCHOLAR-1 study reported an objective response rate (ORR) of only 26% and median OS of 6.3 months in refractory patients. Novel strategies are needed. Chidamide monotherapy showed ORR 25% in R/R DLBCL; PD-1 inhibitors have modest activity; rituximab retreatment is limited by CD20 downregulation. Mechanistically, chidamide upregulates CD20 via epigenetic modulation and remodels the immune microenvironment to enhance PD-1 blockade, while PD-1 inhibition relieves immunosuppression and potentiates rituximab-dependent ADCC. Thus, triple combination is synergistic. No prior study has reported this regimen. This trial evaluates efficacy and safety of chidamide plus PD-1 inhibitor and rituximab.
Methods:
Single-arm, open-label phase II trial (NCT05115409). Eligible: age≥18, histologically confirmed DLBCL (including transformed follicular and high-grade B-cell lymphoma), CD20-positive, refractory/relapsed after at least 2 cycles of a standard first-line rituximab-containing regimen. Refractory defined as failure to achieve PR with last therapy or progression within 6 months after last regimen. Induction: 6 cycles of PCR (zimberelimab 240 mg IV day1; chidamide 30 mg twice weekly days1–21; rituximab 375 mg/m² IV day1). Patients achieving CR or PR received maintenance with same PCR regimen for 1 year (monthly, 12 cycles). CR patients could undergo ASCT. Sample size: assuming expected ORR 50% vs historical 30%, one-sided α=0.0499, β=0.1968, total 46 (two-stage: first 15; if ≤5 responses, stop; else continue; if total responders >18, effective). Enrolled 50 accounting for 10% dropout. Primary endpoint ORR per LYRIC 2016; secondary PFS, OS, safety per CTCAE v5.0.
Results:
Between July 2022 and December 2025, 50 patients were enrolled from 3 Chinese cancer centers. The median age was 55 years (range, 23–85); 60% (n=30) were female, and 72% (n=36) had an Eastern Cooperative Oncology Group performance status (ECOG PS) of ≥1. Advanced stage disease was present in 58% (n=29), and 78% (n=39) of patients were refractory to prior therapy. The IPI score was ≥3 in 26% (n=13), and 60% (n=30) had the non-germinal center B-cell (non-GCB) subtype by Hans algorithm. Double expressor (MYC and BCL2 co-expression) was observed in 5 patients (10%), and double-hit (MYC and BCL2 and/or BCL6 rearrangements) in 2 patients (4%). High proliferative index (Ki-67 >90%) was noted in 14 patients (28%), and bulky disease (>7.5 cm) in 11 patients (22%). The median number of prior lines of therapy was 3 (range, 2–9). Prior treatments included PD-1/PD-L1 inhibitors in 19 patients (38%), ASCT in 5 (10%), CD3×CD20 bispecific antibodies in 5 (10%), and CAR T-cell therapy in 3 (6%). The median number of PCR cycles administered was 4 (range, 1–12). The overall ORR was 50.0% (25/50), with a CR rate of 46.0% (23/50). In subgroup analyses, ORR was higher in patients without bulky disease (56.4% vs. 36.4% in bulky), in relapsed versus refractory patients (63.6% vs. 46.2%), and in those with Ki-67 <90% (55.6% vs. 35.7% in Ki-67 ≥90%). ORR was comparable between GCB and non-GCB subtypes (40% vs. 40%) and between patients with or without prior PD-1 inhibitor exposure (57.9% vs. 45.2%). Among double expressor patients, ORR was 40% (2/5), while double-hit patients achieved an ORR of 100% (2/2). With a median follow-up of 11.9 months (range, 3.2–65.0), the 1-year OS rate was 70.2% and the 1-year PFS rate was 43.0%; the median PFS was 4.3 months. Regarding safety, the most common all-grade adverse events were agranulocytosis (46%), anemia (28%), and thrombocytopenia (20%). Immune-related adverse events included rash (10%) and interstitial pneumonia (10%). Grade ≥3 AEs occurred in a subset of patients, with the most frequent being neutropenia (34%), which was reversible with growth factor support. No treatment-related deaths were reported.
Conclusions:
The PCR study successfully met its prespecified primary efficacy endpoint. The regimen showed encouraging activity across various high-risk subgroups, with manageable and non-cumulative toxicity.These findings support further evaluation of the PCR regimen in earlier lines of therapy and in combination with other novel agents.
DISCLOSURES
Huiqiang Huang, MD, PhD: No relevant conflicts of interest to declare.